Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345–62. https://doi.org/10.1016/S0140-6736(22)01200-4.

Article  CAS  PubMed  Google Scholar 

Lu J, Zhang X-P, Zhong B-Y, Lau WY, Madoff DC, Davidson JC, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019;4:721–30. https://doi.org/10.1016/S2468-1253(19)30178-5.

Article  PubMed  Google Scholar 

Liu P-H, Huo T-I, Miksad R. Hepatocellular Carcinoma with Portal Vein Tumor involvement: best management strategies. Semin Liver Dis. 2018;38:242–51. https://doi.org/10.1055/s-0038-1666805.

Article  CAS  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93. https://doi.org/10.1016/j.jhep.2021.11.018.

Article  PubMed  Google Scholar 

Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice guidelines for the management of Hepatocellular Carcinoma. Korean J Radiol. 2022;23:1126. https://doi.org/10.3348/kjr.2022.0822.

Article  Google Scholar 

Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer. 2020;9:682–720. https://doi.org/10.1159/000509424.

Article  PubMed  PubMed Central  Google Scholar 

Klein J, Dawson LA. Hepatocellular Carcinoma Radiation Therapy: review of evidence and Future opportunities. Int J Radiation Oncology*Biology*Physics. 2013;87:22–32. https://doi.org/10.1016/j.ijrobp.2012.08.043.

Article  Google Scholar 

Park HC, Yu JI, Cheng JC-H, Zeng ZC, Hong JH, Wang MLC, et al. Consensus for Radiotherapy in Hepatocellular Carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): current practice and future clinical trials. Liver Cancer. 2016;5:162–74. https://doi.org/10.1159/000367766.

Article  PubMed  PubMed Central  Google Scholar 

Sun J, Wang Q, Hong Z-X, Li W-G, He W-P, Zhang T, et al. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis. Hepatol Int. 2020;14:788–97. https://doi.org/10.1007/s12072-020-10088-0.

Article  PubMed  Google Scholar 

Su T-S, Liang P, Zhou Y, Huang Y, Cheng T, Qu S, et al. Stereotactic body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: a retrospective, propensity-matched analysis. Front Oncol. 2020;10:347. https://doi.org/10.3389/fonc.2020.00347.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or Radiofrequency ablation for Hepatocellular Carcinoma. JCO. 2016;34:452–9. https://doi.org/10.1200/JCO.2015.61.4925.

Article  CAS  Google Scholar 

Lou J, Li Y, Liang K, Guo Y, Song C, Chen L, et al. Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. BMC Cancer. 2019;19:668. https://doi.org/10.1186/s12885-019-5870-3.

Article  PubMed  PubMed Central  Google Scholar 

Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review. Radiother Oncol. 2018;129:112–22. https://doi.org/10.1016/j.radonc.2017.11.013.

Article  PubMed  Google Scholar 

Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, et al. Stereotactic body Radiation Therapy as an alternative treatment for patients with Hepatocellular Carcinoma Compared to Sorafenib: a propensity score analysis. Liver Cancer. 2019;8:281–94. https://doi.org/10.1159/000490260.

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.

Article  CAS  PubMed  Google Scholar 

Al-Salama ZT, Syed YY, Scott LJ, Lenvatinib. A review in Hepatocellular Carcinoma. Drugs. 2019;79:665–74. https://doi.org/10.1007/s40265-019-01116-x.

Article  CAS  PubMed  Google Scholar 

Ikai I, Yamamoto Y, Yamamoto N, Terajima H, Hatano E, Shimahara Y, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am. 2003;12:65–75. https://doi.org/10.1016/S1055-3207(02)00082-0.

Article  PubMed  Google Scholar 

Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101: stereotactic body radiation therapy: the report of TG101. Med Phys. 2010;37:4078–101. https://doi.org/10.1118/1.3438081.

Article  PubMed  Google Scholar 

Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T, et al. Safety and Pharmacokinetics of Lenvatinib in patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2016;22:1385–94. https://doi.org/10.1158/1078-0432.CCR-15-1354.

Article  CAS  PubMed  Google Scholar 

Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, et al. Dose finding of Lenvatinib in subjects with Advanced Hepatocellular Carcinoma based on Population Pharmacokinetic and exposure-response analyses: the Journal of Clinical Pharmacology. J Clin Pharmacol. 2017;57:1138–47. https://doi.org/10.1002/jcph.917.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72:288–306. https://doi.org/10.1016/j.jhep.2019.09.026.

Article  PubMed  Google Scholar 

Lencioni R, Llovet J. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis. 2010;30:052–60. https://doi.org/10.1055/s-0030-1247132.

Article  CAS  Google Scholar 

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. CTCAE versión 5.0. Evaluación De La Gravedad De Los eventos adversos dermatológicos de las terapias antineoplásicas. Actas Dermosifiliogr. 2021;112:90–2. https://doi.org/10.1016/j.ad.2019.05.009.

Article  CAS  PubMed  Google Scholar 

Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiation Oncology*Biology*Physics. 1995;31:1237–48. https://doi.org/10.1016/0360-3016(94)00418-K.

Article  CAS  Google Scholar 

Liang S-X, Huang X-B, Zhu X-D, Zhang W-D, Cai L, Huang H-Z, et al. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with child–pugh Grade A cirrhosis. Radiother Oncol. 2011;98:265–9. https://doi.org/10.1016/j.radonc.2010.10.014.

Article  PubMed  Google Scholar 

Tao Z-W, Cheng B-Q, Zhou T, Gao Y-J. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review. Hepatobiliary Pancreat Dis Int. 2022;21:134–44. https://doi.org/10.1016/j.hbpd.2021.12.004.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Hilgard P, de Oliveira AC, Forner A, Zeuzem S, Galle PR, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl j Med. 2008. https://doi.org/10.1056/NEJMoa0708857.

Article  PubMed  PubMed Central  Google Scholar 

Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.

Article  CAS  PubMed  Google Scholar 

Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14:84. https://doi.org/10.1186/1471-230X-14-84.

Article